Company Overview of aTyr Pharma Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.
3545 John Hopkins Court
San Diego, CA 92121
Founded in 2005
Key Executives for aTyr Pharma Inc.
Chief Executive Officer and Director
Total Annual Compensation: $472.8K
Total Annual Compensation: $291.2K
Compensation as of Fiscal Year 2015.
aTyr Pharma Inc. Key Developments
aTyr Pharma Inc. Presents Additional Data for Resolaris™ Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society
Oct 6 16
aTyr Pharma Inc. announced that additional clinical data from aTyr's Phase 1b/2 Trial (002) in adult patients with FSHD were presented at the 21st International Congress of the World Muscle Society in Granada, Spain. The presentation includes additional detailed data from the adult FSHD (002) trial covering safety, tolerability, PK, and clinical assessments. Encouraging activity was seen in the patient-reported outcomes, known as the Individualized Neuromuscular Quality of Life Assessment (INQoL), and the physician-reported functional assessment Manual Muscle Testing (MMT). Patients treated with Resolaris were generally improved compared with placebo as assessed by INQoL, with patients in cohort 3 (3.0 mg/kg for 12 weeks) showing the improvement compared with cohort 1 and cohort 2 (0.3 mg/kg and 1.0 mg/kg for 4 weeks respectively). Patients in cohort 3 reported a 9.9% improvement in INQoL compared with a 15.6% worsening in the placebo group at week 14. Five out of the six patients on Resolaris in cohort 3 showed overall improvement in their INQoL score at week 14, versus zero out of two patients on placebo. A trend for improvement in MMT results with Resolaris treatment was also observed compared with placebo, especially in the upper limbs. In general, there was an association between changes in INQoL and MMT, whereby all patients who experienced an improvement in muscle function also showed improvement in INQoL scores. Patients in cohort 3 reported 0.7% improvement in MMT compared with 1.4% worsening in the placebo group at week 14. Three out of the six patients on Resolaris in cohort 3 showed overall improvement in their MMT score at week 14, versus zero out of two patients on placebo. Conclusions of the Adult FSHD (002) Trial: Over the dose and duration studied, Resolaris was found to be generally safe in adult patients with FSHD, and was generally well tolerated with the exception of one patient who experienced infusion related reactions as previously reported and as discussed in more detail in poster presentation. PK properties were dose-proportional and generally consistent throughout the study, with no measurable impact from anti-drug antibodies (ADAs). Clinical activity was supported by signals of improvement in INQoL questionnaire responses and MMT measures. Other exploratory measures, including lower extremity targeted MRI, did not demonstrate activity. Variability in image acquisition may have diminished the opportunity to show activity in this measurement. Patients in cohorts 2 and 3 were allowed to enroll in the ongoing long-term extension study (005) investigating the safety and efficacy of Resolaris, for which aTyr expects to provide an update in December 2016.
aTyr Pharma Inc. Joins David J. King as Senior Vice President, Research
Sep 21 16
aTyr Pharma Inc. announced that David J. King, PhD, has joined the company as Senior Vice President, Research. Dr. King will lead aTyr's research and preclinical efforts to advance its Physiocrine biology and support the clinical development of meaningful medicines that target immune and tissue homeostatic pathways for patients with various severe and rare diseases.
aTyr Pharma Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
Aug 10 16
aTyr Pharma Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported loss from operations of $15,433,000 against $10,898,000 a year ago. Net loss was $15,383,000 against $11,080,000 a year ago. Net loss attributable to common stockholders was $15,383,000 or $0.65 per share basic and diluted against $11,095,000 or $0.74 per share basic and diluted a year ago.
For the six months, the company reported loss from operations of $31,548,000 against $19,820,000 a year ago. Net loss was $31,470,000 against $20,151,000 a year ago. Net loss attributable to common stockholders was $31,470,000 or $1.33 per share basic and diluted against $20,166,000 or $2.53 per share basic and diluted a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|